United Kingdom Spinal Muscular Atrophy Therapeutics Market Expected to Grow Faster According to New Research Report 2023-2028

Report Overview

The UK Spinal Muscular Atrophy Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Spinal Muscular Atrophy (SMA) is a group of genetic neuromuscular disorders that affect the nerve cells that control voluntary muscles (motor neurons). The loss of motor neurons causes progressive muscle weakness and loss of movement due to muscle wasting (atrophy). The severity of the symptoms, the age at which symptoms, begin, and the genetic cause varies by type. Many types of SMA mainly affect the muscles involved in walking, sitting, arm movement, and head control. Breathing and swallowing may also become difficult as the disease progresses in many types of SMA. In some types of SMA, the loss of motor neurons makes it hard to control the movement of the hands and feet.

SMA types 1, 2, 3, and 4 are caused by changes (or pathogenic mutations) in the SMN1 gene and are inherited in an autosomal recessive manner. The disease generally manifests early in life and is the leading genetic cause of death in infants and toddlers. SMA is caused by defects in the Survival Motor Neuron 1 (SMN1) gene that encodes the SMN protein. The SMN protein is critical to the health and survival of the nerve cells in the spinal cord responsible for muscle contraction (motor neurons).

SMA is one of the most common rare diseases. In the UK approximately 100 children are born with this rare disease each year. Moreover, there are between some 1200 - 2500 children and adults in the UK living with SMA. Approximately one in every 40-60 people is an SMA carrier, which is approximately 1.5 million people in the UK. Approximately one in 6,000 babies born have SMA, and about one in 40 people carry a copy of the altered gene that causes the condition (although they do not have the condition themselves).

Market Growth Drivers

The overall burden of spinal muscular atrophy is one of the highest in terms of cost and healthcare services in rare disorders. The rising incidence of spinal muscular atrophy due to the increasing population is one of the key factors for the growth in the SMA treatment market. This growth is attributed to the rapidly developing health infrastructure in the UK, the initiatives are undertaken by various public, as well as non-profit, organizations for creating awareness regarding SMA, have increased remarkably which is propelling the demand for efficient therapeutic options leading to better patient outcomes.

An increase in R&D investment by major companies will boost the market growth in the forecast period. Granting various drug designation to novel drugs is also accelerating the market growth for spinal muscular atrophy treatment. In recent times, there have been few substantial and very significant product launches in gene therapy for the treatment of spinal muscular atrophy disease.

Market Restraints

However, the high cost of treatment for spinal muscular atrophy is hindering market growth. Additionally, the lack of experienced professionals and less adoption rate of spinal muscular atrophy treatment options is also restraining the market growth.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139934/

Top Major Players

The UK spinal muscular atrophy treatment market is a highly competitive market and major key players are adopting strategies; organic as well as inorganic market strategies. Evrysdi is the only oral-approved drug with the reported list price of £7,900 per 60 mg vial for people with types 1, 2, and 3 SMA while other prominent drugs are administered by the parenteral route and thus possess better efficacy. The prominent key players prevailing in the UK market are Biogen Idec Research Limited, Genentech-Roche Pharmaceuticals Inc, Novartis UK Limited, and Ionis Pharmaceuticals among others.

The United Kingdom Spinal Muscular Atrophy Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global United Kingdom Spinal Muscular Atrophy Therapeutics market. This report explores all the key factors affecting the growth of the global United Kingdom Spinal Muscular Atrophy Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On United Kingdom Spinal Muscular Atrophy Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139934/

Market Segmentation

By Disease Type:

On the basis of disease type, the spinal muscular atrophy treatment market has been segmented into

Type 1 SMA
Type 2 SMA
Type 3 SMA
Type 4 SMA

Type 1 SMA generated the highest revenue amongst all the categories in 2020. Thus, type 1 SMA is anticipated to remain the most dominant in terms of revenue as the majority of the cases of the disorder are of this type, which has led to it dominating in terms of market share. Increasing awareness of the Type 2 SMA and increasing adoption of treatment is also anticipated to drive the growth of this type over the forecast period.

By Diagnosis:

On the basis of diagnosis, the spinal muscular atrophy treatment market can be classified into

Physical examination
Electromyography
Muscle Biopsy
Genetic Counselling
Chorionic villus sampling (CVS)
Amniocentesis
Genetic Blood Test
Others

A physical examination may be done to look for signs of SMA or similar conditions. Electromyography and muscle biopsy have also been used. Genetic counseling helps you to understand that if you're at risk of having a child with SMA. While chorionic villus sampling (CVS), and Amniocentesis are usually carrying out during pregnancy. If the child has typical symptoms of SMA, a genetic blood test can be done to confirm the condition.

By Therapeutics:

Based on the therapeutics, the spinal muscular atrophy treatment market can be bifurcated into

Evrysdi (risdiplam)
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec)
Physical Therapy
Chest Physiotherapy
Nutritional therapy
Use of Ventilators

Nusinersen has been accounted for the maximum share in 2020, which is attributable to the fact that Nusinersen is the most effective drug among others in the market and possesses Orphan market exclusivity expiry till 1 Jun 2029. However, Zolgensma (Onasemnogene Abeparvovec) who gained approval later after Spinraza (which costs £450,000 for the first year and £225,000 for subsequent years), however expected to witness growth in the coming years owing to the rising incidence of spinal muscular atrophy disease and the greater patient adoption rate but this very costly innovative gene therapy with a reported list price of £1.79 million ($2.48 million) per dose, might limit its application in the UK, NHS England said in a statement.

By Distribution Channels:

In terms of distribution channel, the spinal muscular atrophy treatment market can be categorized into

Hospital pharmacies
Retail pharmacies
Online pharmacies

In terms of value, the hospital pharmacies accounted for the leading market share in 2020, which is attributable to the fact that the majority of the medications for spinal muscular atrophy treatment can be only administered intravenously and can so only be done by trained medical professionals. Hence, the hospital pharmacies segment is anticipated to enhance the market share over the forecast period.

Top Major Players

The UK spinal muscular atrophy treatment market is a highly competitive market and major key players are adopting strategies; organic as well as inorganic market strategies. Evrysdi is the only oral-approved drug with the reported list price of £7,900 per 60 mg vial for people with types 1, 2, and 3 SMA while other prominent drugs are administered by the parenteral route and thus possess better efficacy. The prominent key players prevailing in the UK market are Biogen Idec Research Limited, Genentech-Roche Pharmaceuticals Inc, Novartis UK Limited, and Ionis Pharmaceuticals among others.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139934/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global United Kingdom Spinal Muscular Atrophy Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global United Kingdom Spinal Muscular Atrophy Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the United Kingdom Spinal Muscular Atrophy Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the United Kingdom Spinal Muscular Atrophy Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the United Kingdom Spinal Muscular Atrophy Therapeutics
Chapter 4: Presenting the United Kingdom Spinal Muscular Atrophy Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the United Kingdom Spinal Muscular Atrophy Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139934/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the United Kingdom Spinal Muscular Atrophy Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.